Suchergebnisse - "Engelhardt, Monika"

PubPharm (17)

1

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma : A subanalysis of OPTIMISMM by clinical characteristics

enthalten in: European journal of haematology | 2022

von Richardson, P. | Schjesvold, F. | Weisel, K. | +25

2

Carfilzomib, bendamustine, and dexamethasone in patients with advanced multiple myeloma : The EMN09 phase 1/2 study of the European Myeloma Network

enthalten in: Cancer | 2021

von Gay, F. | Günther, A. | Offidani, M. | +17

3

Quality of life analyses in patients with multiple myeloma : results from the Selinexor (KPT-330) Treatment of Refractory Myeloma (STORM) phase 2b study

enthalten in: BMC cancer | 2021

von Tremblay, G. | Daniele, P. | Breeze, J. | +39

4

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM) : outcomes by prior treatment at first relapse

enthalten in: Leukemia | 2021

von Dimopoulos, M. | Weisel, K. | Moreau, P. | +17

5

Validation of the revised myeloma comorbidity index and other comorbidity scores in a multicenter German study group multiple myeloma trial

enthalten in: Haematologica | 2021

von Dold, S. | Möller, M. | Ihorst, G. | +8

6

Real-World Evaluation of Health-Related Quality of Life in Patients With Multiple Myeloma From Germany

enthalten in: Clinical lymphoma, myeloma & leukemia | 2021

von Engelhardt, M. | Ihorst, G. | Singh, M. | +4

7

Clinical characteristics and outcome of multiple myeloma patients with concomitant COVID-19 at Comprehensive Cancer Centers in Germany

enthalten in: Haematologica | 2020

von Engelhardt, M. | Shoumariyeh, K. | Rösner, A. | +14

8

MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma : a first-in-human, multicentre, phase 1-2a trial

enthalten in: The Lancet. Haematology | 2020

von Raab, M. | Engelhardt, M. | Blank, A. | +15

9

Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Mateos, M. | Blacklock, H. | Schjesvold, F. | +119

CommentIn: Ann Transl Med. 2020 Jun;8(12):777. - PMID 32647702

10

Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185) : a randomised, open-label, phase 3 trial

enthalten in: The Lancet. Haematology | 2019

von Usmani, S. | Schjesvold, F. | Oriol, A. | +115

CommentIn: Lancet Haematol. 2019 Sep;6(9):e439-e440. - PMID 31327688